Efavirenz liquid formulation in human immunodeficiency virus-infected children
作者:
STUART STARR,
COURTNEY FLETCHER,
STEPHEN SPECTOR,
RICHARD BRUNDAGE,
FLORENCE YONG,
STEVEN DOUGLAS,
PATRICIA FLYNN,
MARK KLINE,
期刊:
The Pediatric Infectious Disease Journal
(OVID Available online 2002)
卷期:
Volume 21,
issue 7
页码: 659-663
ISSN:0891-3668
年代: 2002
出版商: OVID
关键词: Perinatal human immunodeficiency virus transmission;elective cesarean delivery;antiretroviral therapy;North Carolina
数据来源: OVID
摘要:
Background.This study determined the safety, pharmacokinetics, antiviral activity and immunologic effects of efavirenz liquid formulation, nelfinavir and nucleoside reverse transcriptase inhibitors (NRTIs) in HIV-infected children, 3 to 9 years of age.Methods.Plasma HIV-1 RNA and lymphocyte subsets were measured at various intervals after initiation of therapy. Pharmacokinetic studies were performed at Week 2, and doses of efavirenz and nelfinavir were adjusted if area under the curve values fell outside specified target ranges.Results.This combination of antiretrovirals was well-tolerated. Pharmacokinetic values were similar to those observed in a previous study of older children who received efavirenz capsules in combination with nelfinavir and NRTIs. After 48 weeks of therapy 63% of subjects had plasma HIV RNA levels of <400 copies/ml, and 58% had <50 copies/ml in an intent-to-treat analysis. CD4 cell count and percentage rose significantly over this time, whereas the number of activated CD8 cells declined.Conclusions.Combination therapy with efavirenz liquid formulation, nelfinavir and NRTIs is an attractive treatment option for HIV-infected children >3 years of age who are unable to take efavirenz capsules.
点击下载:
PDF
(95KB)
返 回